Aurobindo Pharma, a mid-size pharmaceutical company, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Flecainide Acetate Tablets USP 50 mg, 100 mg and 150 mg (ANDA 202821).

According to IMS, Flecainide Acetate Tablets are an antiarrhythmic agent with an estimated market size of USD 61 million for the twelve months ending April 2015.

This is the 40th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-betalactam products.

Shares of the company gained Rs 10.2, or 0.7%, to trade at Rs 1,461.35. The total volume of shares traded was 28,576 at the BSE (10.28 a.m., Friday).